Abstract
Systemic infection is a major cause of mortality and morbidity among premature neonates. In this fragile population, the immaturity of the innate immune response relates inversely to gestational age and is one of the determinants of susceptibility to infections. Antibiotic therapy, even when appropriately and timely instituted, may fail to prevent death or significant sequelae. The quest for additional strategies is still open; in this scenario, the supplementation with exogenous immunoglobulins represents an attractive additional strategy of defence. As current data are conflicting, we provide a critical appraisal with a focus on IgM enriched immunoglobulins preparations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
